

# Imaging for BVS

BioResorbable Vascular Scaffold

Roh Jin Seok, RT

Asan Medical Center



# Bioabsorbable Coatings in Perspective


## Relative Coating Thickness

Scaffold mounted on the balloon



	SYNERGY™ Stent <sup>1</sup>	Xience™ Stent <sup>2</sup>	BioMatrix Flex™ Stent <sup>3</sup>	Absorb™ BVS <sup>4</sup>
<b>Strut Thickness</b>	74 μm (0.0029")	81 μm (0.0032")	120 μm (0.0047")	150 μm (0.0059")
<b>Polymer Coating Type &amp; Thickness</b>	Bioabsorbable Abluminal 4μm	Conformal Durable 8μm	Bioabsorbable Abluminal 10μm	Bioabsorbable Conformal 3μm / side
<b>Total Coated Strut Thickness</b>	78μm	97μm	130μm	156μm

# Scaffold mounted on the balloon



**Use balloon markers to position scaffold**

# Locating Scaffold Marker Beads

Only balloon catheter markers are visible


During delivery  
(scaffold crimped on balloon)

Scaffold markers  
Balloon catheter marker  
Balloon catheter marker


Scaffold markers  
Balloon catheter markers  
After Deployment

# IVUS Image

TM: 03  
1850/2273




**DES**




**BVS**



# OCT Image




**DES**



**BVS**

# BVS - IVUS OCT Image



**BVS - OCT**


**BVS - IVUS**

# The **PREVENT**ive Implantation of Bioresorbable Vascular Scaffold on Stenosis With Functionally Insignificant Vulnerable Plaque

## **PREVENT Trial**

**Any Significant Epicardial Coronary Stenosis ( $DS > 50\%$ )  
with  $FFR > 0.80$  and with Two of the following**

1. MLA  $< 4.0\text{mm}^2$
2. Plaque Burden at MLA site  $> 70\%$
3. Lipid-Rich Plaque on NIRS ( $\text{max LCBI}_{4\text{mm}} > 315$ )
4. TCFA defined by OCT or VH-IVUS







### **TCFA**


- OCT definition: fibrous cap thickness  $< 65\ \mu\text{m}$  and arc  $> 90^\circ$
- VH-IVUS definition:  $\geq 10\%$  confluent NC with  $> 30^\circ$  abutting to the lumen in 3 consecutive slices



# CASE - I




# CASE - I




**NC Balloon 3.0mm**



# CASE - I





**BVS 3.0 / 23mm**




**NC Balloon 3.0mm**

# CASE - I




**NC Balloon 3.5mm**







**NC Balloon 3.0mm**



**NC Balloon 3.5mm**



# Operating Protocol of BVS



For lesion preparation, it is generally advisable to use semi- or non-compliant balloons with a diameter equal to or only minimally undersized compared to the diameter of the selected BVS delivery system. Short (6 to 10 mm long) high-pressure balloons should be used after predilation of the segments when lesions show focal residual underexpansion due to the presence of highly calcific atherosclerotic plaques. Although no supporting data are available, the use of plaque modification devices (i.e., cutting/scoring balloons, rotational atherectomy) is encouraged when necessary to enable the BVS to cross and better expand calcified stenoses, but in the authors' experience this is rarely required. In the event that one cannot achieve full opening of the (last) predilatation balloon with no indentation, it is advisable not to implant a BVS.


Due to the polymeric material, the BVS has a maximum scaffold expansion limit of 0.5 mm above its nominal diameter, which should be respected strictly during implantation. Upon scaffold deployment, one should aim to obtain <10% residual stenosis, full scaffold expansion and optimal wall apposition. Therefore, routine post-dilatation for 10-30 seconds using a high-pressure non-compliant balloon is advisable unless intracoronary imaging confirms full expansion and apposition.

Figure 1. Practical operating protocol for new users of BVS.

Tamburino C. EuroIntervention 2015 May;11(1):45-52




# ScT – Scaffold thrombosis




**Figure 1.** Early scaffold thrombosis (ScT). **A**, ScT 6 days after scaffold implantation for inferior ST-elevation myocardial infarction. Optical coherence tomography revealed undersizing in the proximal part of the scaffold as the key mechanism for ScT. **B**, ScT 8 days after scaffold implantation for non-ST-elevation myocardial infarction. Optical coherence tomography revealed underexpansion as the key mechanism for ScT: 3D reconstruction demonstrates an underexpanded distal segment with good expansion in the proximal segment of the scaffold.

# BVS Incomplete apposition





**BVS - IVUS**



**BVS - OCT**




# CASE - II



**BVS 3.5 / 28 mm**




# CASE - II




**BVS 3.5 / 12 mm**

# CASE - II






# CASE - II






# BVS Overlap



**BVS - IVUS**



**BVS - OCT**


# CASE - III




**NC Balloon 2.75mm**



# CASE - III





**BVS 3.0 / 23mm**



**NC Balloon 3.5mm**



# CASE - III






# CASE - III

LEE JONG HOON  
D: 50025910 M53  
\* 0001-01-01, M  
Study 5002591020151118  
1 IMA 2273 FRM 2094

AMC  
iLab



W: 256  
C: 127



## Proximal Edge Dissection





UNIVERSITY OF ULSAN  
COLLEGE OF MEDICINE



ASAN  
Medical Center


# CASE - IV




**NC Balloon 2.75 mm**



# CASE - IV




**BVS 3.0 / 28mm**



**NC Balloon 3.0mm**





# CASE - IV



**NC Balloon 3.0mm**




# CASE - IV



Distal Edge Dissection

# Post HP Balloon Inflation





# Summary

- **IVUS** has advantage of visualising the total vessel diameter and area, which allows optimization of scaffold size while reducing the risk of disruption with oversized balloons.
- **OCT** has higher resolution, so that scaffold integrity, apposition to the underlying wall. Presence of thrombus, edge dissections, and changes in strut characteristics over time can be easily studied.

Tamburino C. EuroIntervention 2015 May;11(1):45-52

